Ozempic, Wegovy and Zepbound get new FDA warning over rare condition

People taking popular weight-loss and diabetes drugs are getting a new safety warning. The Food and Drug Administration is requiring all GLP-1 drugs to carry information about a potential increased risk of a rare eye condition that can cause permanent vision loss, according to the FDA’s Nov. 9 drug safety communication. The medications include Ozempic, Wegovy, Mounjaro and Zepbound.